This study demonstrates that potential breast milk exposure to interferon-beta (IFN-β) or glatiramer acetate (GA), does not increase the risk of adverse infant events. Thus, women with multiple sclerosis (MS) taking INF-β or GA postpartum may be encouraged to breastfeed due to the positive health outcomes associated with breastfeeding.
Why this matters
Breastfeeding mothers with MS are concerned about the breast milk exposure of disease-modifying therapies (DMTs) and the potential health risks to their child.
Currently, there is little data available on breastfeeding while taking DMTs.